Cyto-Facto

Cyto-Facto is a Japanese Contract Development and Manufacturing Organization (CDMO) that specializes in the production of cell and gene therapies. Established as a spin-off from the Foundation for Biomedical Research and Innovation at Kobe (FBRI), the company leverages over two decades of expertise in regenerative medicine and cell processing. Cyto-Facto provides a comprehensive suite of services, including process development, analytical testing, and clinical-to-commercial scale manufacturing under GCTP/GMP standards. Their state-of-the-art facilities are designed to handle complex modalities such as CAR-T cells and induced pluripotent stem cells (iPSCs). By integrating advanced automation and rigorous quality control, Cyto-Facto aims to accelerate the delivery of innovative living medicines to patients globally. The company is a key player in the Kobe Biomedical Innovation Cluster, supporting both academic and industrial partners.